12 results on '"Groenier, Klaas H."'
Search Results
2. Inflammation biomarkers and mortality prediction in patients with type 2 diabetes (ZODIAC-27).
- Author
-
Landman, Gijs W.D., Kleefstra, Nanne, Groenier, Klaas H., Bakker, Stephan J.L., Groeneveld, Geert H., Bilo, Henk J.G., and van Hateren, Kornelis J.J.
- Subjects
- *
PEOPLE with diabetes , *MORTALITY , *BIOMARKERS , *C-reactive protein , *ADRENOMEDULLIN , *COHORT analysis , *PROPORTIONAL hazards models - Abstract
Background C-reactive protein (CRP), procalcitonin (PCT) and pro-adrenomedullin (MR-proADM) are inflammation markers associated with long-term mortality risk. We compared the associations and predictive capacities of CRP, PCT and MR-proADM with cardiovascular and all-cause mortality in patients with type 2 diabetes. Methods This study included primary care treated patients with type 2 diabetes participating in the ZODIAC cohort study. A total of 1005 out of 1688 patients (60%) had complete baseline variables. Baseline CRP, PCT and MR-proADM were assessed in relation to cardiovascular and all-cause mortality with Cox proportional hazard analyses. Hazard Ratios (HR) were adjusted for age, gender, BMI, smoking, systolic blood pressure, cholesterol-HDL ratio, duration of diabetes, HbA 1c , history of cardiovascular diseases, albumin-creatinine ratio and creatinine. Risk prediction capabilities were assessed with Harrell's C statistics and proportion of explained variance ( R 2 ). Results After a median follow-up of 11 years, 472 (47%) of 1005 patients had died. The likelihood ratio test showed that CRP and MR-proADM significantly improved prediction in cardiovascular mortality [HRs 1.20 (95%CI 1.09–1.33) and 1.56 (95%CI 1.06–2.30)] and in all-cause mortality [HRs 1.10 (95%CI: 1.03–1.18) and 1.31 (95%CI 1.02–1.69)]. Harrell's C values and R 2 measures showed slightly improved discrimination for cardiovascular mortality in patients without macrovascular disease (C: 0.80 to 0.81; R 2 : 0.50 to 0.52) and MR-proADM (C: 0.80 to 0.82; R 2 : 0.50 to 0.52). Conclusions CRP and MR-proADM, but not PCT, were independently associated with cardiovascular and all-cause mortality. In patients without macrovascular diseases, CRP and MR-proADM slightly improved discrimination, in absolute sense, of patients at risk for cardiovascular mortality. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
3. Is the association of serum sodium with mortality in patients with type 2 diabetes explained by copeptin or NT-proBNP? (ZODIAC-46).
- Author
-
Riphagen, Ineke J., Logtenberg, Susan J.J., Groenier, Klaas H., van Hateren, Kornelis J.J., Landman, Gijs W.D., Struck, Joachim, Navis, Gerjan, Kootstra-Ros, Jenny E., Kema, Ido P., Bilo, Henk J.G., Kleefstra, Nanne, and Bakker, Stephan J.L.
- Subjects
- *
PEOPLE with diabetes , *BLOOD serum analysis , *MORTALITY , *PHYSIOLOGICAL effects of sodium , *HYPONATREMIA , *VASOPRESSIN , *COPEPTINS , *DISEASE risk factors - Abstract
Background and aims Hyponatremia has been associated with an increased mortality risk in the general population. Diabetes is a condition predisposing for elevated levels of arginine vasopressin (AVP) and heart failure, both common causes of hyponatremia. These factors, however, are also associated with an increased mortality risk. We aimed to investigate whether serum sodium is associated with cardiovascular and all-cause mortality in type 2 diabetes and whether these associations could be explained by copeptin, a surrogate for AVP, or NT-proBNP, a marker for heart failure. Methods Patients with type 2 diabetes participating in the observational ZODIAC study were included. Cox regression analyses were used to investigate the association of serum sodium with mortality. Results We included 1068 patients (age 67 ± 12 years, 45% male, serum sodium 142 ± 3 mmol/L). After 15 years of follow-up, 519 patients (49%) died, with 225 cardiovascular deaths (21%). In univariable analyses, serum sodium, copeptin, and NT-proBNP were all significantly associated with cardiovascular and all-cause mortality. These associations remained significant after combination of these markers in a multivariable model. Serum sodium and NT-proBNP remained significantly associated with mortality after further adjustment for potential confounders, whereas copeptin lost significance after adjustment for SCr and ACR. Conclusion Low serum sodium was associated with an increased risk of cardiovascular and all-cause mortality in type 2 diabetes. Moreover, these associations were not explained by copeptin and NT-proBNP. Whether low serum sodium itself leads to poor outcome or is a marker for (unidentified) co-morbidity severity or use of specific medications remains to be elucidated. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
4. Effects of three frequencies of self-monitored blood glucose on HbA1c and quality of life in patients with type 2 diabetes with once daily insulin and stable control: a randomized trial.
- Author
-
Hortensius, Johanna, Kleefstra, Nanne, Landman, Gijs W. D., Houweling, Bas T., Groenier, Klaas H., van der Bijl, Jaap J., and Bilo, Henk
- Subjects
- *
PEOPLE with diabetes , *BLOOD sugar , *GLYCOSYLATED hemoglobin , *QUALITY of life , *TYPE 2 diabetes treatment - Abstract
Objective: The optimal frequency of self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes (T2DM) with stable glycemic control is unknown. This study investigated effects of 3 frequencies of SMBG on glycemic control and quality of life after 9 months in patients using one long-acting insulin injection a day. In an openlabel, multi-center, primary-care, parallel (1:1:1) randomized trial in the Netherlands including patients with T2DM, HbA1c ≤ 58 mmol/mol (≤ 7.5%), stable glycemic control, treated with one insulin injection daily, three frequencies of 4-point glucose measurements (before meals and bedtime) were weekly (n = 22), every 2 weeks (n = 16) and monthly (n = 20) were compared. Results: A total of 58 patients with T2DM were included by 38 general practitioners, which was lower then anticipated. There were no significant between group differences in HbA1c (mmol/mol); group C compared to A and B; - 2.7 (95% CI - 6.4, 1.0) and - 1.0 (95% CI - 4.9, 3.0) and quality of life. Baring in mind the lower than anticipated inclusion rate, there were no significant differences in HbA1c and quality of life between three different frequencies of SMBG in patients with stable glycemic control using one long-acting insulin injection. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
5. Addition of sulphonylurea to metformin does not relevantly change body weight: a prospective observational cohort study ( ZODIAC-39).
- Author
-
Schrijnders, Dennis, Wever, Raiza, Kleefstra, Nanne, Houweling, Sebastiaan T., van Hateren, Kornelis J. J., de Bock, Geertruida H., Bilo, Henk J. G., Groenier, Klaas H., and Landman, Gijs W. D.
- Subjects
- *
METFORMIN , *HYPOGLYCEMIC agents , *TREATMENT of diabetes , *PEOPLE with diabetes , *BODY mass index , *HEALTH - Abstract
Aim To investigate changes in body weight trajectories after the addition of individual sulphonylureas ( SUs) to metformin in patients with type 2 diabetes. Materials and methods We conducted a retrospective observational cohort study, in a primary care setting in the Netherlands. Patients aged ≥18 years with type 2 diabetes who were included in the ZODIAC cohort between 1998 and 2012 and who received metformin monotherapy at inclusion (n = 29 195), and had used metformin as monotherapy for at least 1 year before receiving dual therapy through the addition of an SU for at least 1 year were eligible for inclusion. The primary outcome was within-drug yearly change in body weight after receiving add-on therapy with individual SUs during 5 years of follow-up. The secondary outcome was within-drug yearly change in glycated haemoglobin ( HbA1c). Annual changes in weight and HbA1c were estimated with linear mixed models, adjusted for age, gender and diabetes duration. Results A total of 2958 patients were included. No significant weight changes were observed within and between any of the individual SUs after treatment intensification (p = 0.24). In addition, no significant difference in weight between the add-on therapy combinations was observed (p = 0.26). The average HbA1c the year before intensification was 7.2% (55 mmol/mol) and dropped below 7.0% (53 mmol/mol) the year after. Conclusions In patients with type 2 diabetes treated in primary care, strict glycaemic control can be maintained with SUs used as add-on therapy to metformin, without the offset of relevant weight changes. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
6. Demographical, Clinical, and Psychological Characteristics of Users and Nonusers of an Online Platform for T2DM Patients (e-VitaDM-3/ZODIAC-44).
- Author
-
Roelofsen, Yvonne, van Vugt, Michael, Hendriks, Steven H., van Hateren, Kornelis J. J., Groenier, Klaas H., Snoek, Frank J., Kleefstra, Nanne, Huijsman, Robbert, and Bilo, Henk J. G.
- Subjects
- *
DIABETES , *PEOPLE with diabetes , *MEDICAL quality control , *QUALITY of life , *WELL-being , *HYPERTENSION , *COMPUTER network resources - Abstract
Background. Online platforms offer opportunities for support in changing lifestyle and taking responsibility for one’s health, but engaging patients with type 2 diabetes is challenging. Previous studies have shown that patients interested in platforms were more often male, younger, and higher educated. This study aims to investigate differences in clinical and psychological characteristics between users and nonusers of a newly developed platform. Methods. A prospective study started in the Drenthe region of Netherlands. Participants in the study concerning quality of care and quality of life were additionally invited to use the platform. Results. 633 patients were registered after they opted for platform use. Of these patients, 361 (57.0%) never logged on, 184 (29.1%) were labeled “curious” users, and 88 (13.9%) were identified as “active” users. Users had lower HbA1c levels and more often hypertension compared to nonusers, and reported higher quality of life, better well-being, lower diabetes-related distress, and better medication adherence. Discussion. Platform use was associated with more favorable clinical and psychological characteristics relative to nonuse. Those with greater severity of disease, lower mood, and progression of disease used the platform the least. Other approaches need to be developed to reach these patients. Furthermore, improving the platform could also help to reach them. This trial is registered with Clinicaltrials.gov
NCT01570140 . [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
7. Serum Proenkephalin A Levels and Mortality After Long-Term Follow-Up in Patients with Type 2 Diabetes Mellitus (ZODIAC-32).
- Author
-
van Hateren, Kornelis J. J., Landman, Gijs W. D., Arnold, Jarinke F. H., Joosten, Hanneke, Groenier, Klaas H., Navis, Gerjan J., Sparwasser, Andrea, Bakker, Stephan J. L., Bilo, Henk J. G., and Kleefstra, Nanne
- Subjects
- *
PEOPLE with diabetes , *BLOOD serum analysis , *ENKEPHALINS , *DIABETES , *MORTALITY , *FOLLOW-up studies (Medicine) , *HEART failure - Abstract
Background: Two previous studies concluded that proenkephalin A (PENK-A) had predictive capabilities for stroke severity, recurrent myocardial infarction, heart failure and mortality in patients with stroke and myocardial infarction. Objectives: This study aimed to investigate the value of PENK-A as a biomarker for predicting mortality in patients with type 2 diabetes mellitus. Methods: Patients with type 2 diabetes mellitus were included from the prospective observational ZODIAC (Zwolle Outpatient Diabetes project Integrating Available Care) study. The present analysis incorporated two ZODIAC cohorts (1998 and 2001). Since blood was drawn for 1204 out of 1688 patients (71%), and information on relevant confounders was missing in 47 patients, the final sample comprised 1157 patients. Cox proportional hazard models were used for evaluating the relationship between PENK-A and (cardiovascular) mortality. Risk prediction capabilities were assessed with Harrell’s C statistics and the integrated discrimination improvement (IDI). Results: After a follow-up period of 14 years, 525 (45%) out of 1157 patients had died, of which 224 (43%) were attributable to cardiovascular factors. Higher Log PENK-A levels were not independently associated with increased (cardiovascular) mortality. Patients with PENK-A values in the highest tertile had a 49% (95%CI 1%-121%) higher risk of cardiovascular mortality compared to patients in the reference category (lowest tertile). C-values were not different after removing PENK-A from the Cox models and there were no significant differences in IDI values. Conclusions: The associations between PENK-A and mortality were strongly attenuated after accounting for all traditional risk factors. Furthermore, PENK-A did not seem to have additional value beyond conventional risk factors when predicting all-cause and cardiovascular mortality. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
8. Midregional Fragment of Proadrenomedullin, New-Onset Albuminuria, and Cardiovascular and All-Cause Mortality in Patients With Type 2 Diabetes (ZODIAC-30).
- Author
-
Landman, Gijs W. D., van Dijk, Peter R., Drion, Iefke, van Hateren, Kornelis J. J., Struck, Joachim, Groenier, Klaas H., Gans, Rijk O. B., Bilo, Henk J. G., Bakker, Stephan J. L., and Kleefstra, Nanne
- Subjects
- *
ADRENOMEDULLIN , *PEOPLE with diabetes , *ALBUMINURIA , *CREATININE , *MORTALITY , *DIABETES - Abstract
The midregional fragment of proadrenomedullin (MR-proADM) is a marker of endothelial dysfunction and has been associated with a variety of diseases. Our aim was to investigate whether MR-proADM is associated with new-onset albuminuria and cardiovascular (CV) and all-cause mortality in patients with type 2 diabetes treated in primary care. RESEARCH DESIGN AND METHODS Patients with type 2 diabetes participating in the observational Zwolle Outpatient Diabetes Project Integrating Available Care (ZODIAC) study were included. Cox regression analyses were used to assess the relation of baseline MR-proADM with new-onset albuminuria and CV and all-cause mortality. Risk prediction capabilities of MR-proADM for new-onset albuminuria and CV and all-cause mortality were assessed with Harrell's C and the integrated discrimination improvement. RESULTS In 1,243 patients (mean age 67 [±12] years), the median follow-up was 5.6 years (interquartile range 3.1-10.1); 388 (31%) patients died, with 168 (12%) CV deaths. Log2 MR-proADM was associated with CV (hazard ratio 1.96 [95% CI 1.27-3.01]) and all-cause mortality (1.78 [1.34-2.36]) after adjusting for age, sex, BMI, smoking, systolic blood pressure, cholesterol-to-HDL ratio, duration of diabetes, HbA1c, ACE inhibitor/angiotensin receptor blocker, history of CV diseases, log serum creatinine, and log albumin-to-creatinine ratio. MR-proADM slightly improved mortality risk prediction. The age- and sex-adjusted, but not multivariate-adjusted, MR-proADM levels were associated with new-onset albuminuria. CONCLUSIONS MR-proADM was associated with CV and all-cause mortality in patients with type 2 diabetes after a median follow-up of 5.6 years. There was no independent relationship with new-onset albuminuria. In the availability of an extensive set of risk factors, there was little added effect of MR-proADM in risk prediction of CV and all-cause mortality. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
9. The Midregional Fragmentof Pro-A-Type Natriuretic Peptide, Blood Pressure, and Mortality in a Prospective Cohort Study of Patients With Type 2 Diabetes (ZODIAC-25).
- Author
-
VAN HATEREN, KORNELIS J. J., LANDMAN, GIJS W. D., KLEEFSTRA, NANNE, GROENIER, KLAAS H., STRUCK, JOACHIM, NAVIS, GERJAN J., BAKKER, STEPHAN J. L., HOUWELING, SEBASTIAAN T., VAN DER MEER, KLAAS, and BILO, HENK J. G.
- Subjects
- *
NATRIURETIC peptides , *PEOPLE with diabetes , *PROPORTIONAL hazards models , *BLOOD pressure , *DIABETES , *MORTALITY - Abstract
OBJECTIVE--Evidence that midregional fragment of pro-A-type natriuretic peptide (MR-proANP) is a marker of mortality in patients with type 2 diabetes is limited. Therefore, we aimed to investigate the capabilities of MR-proANP in predicting mortality. We also investigated whether MR-proANP influences the relationship between blood pressure and mortality in old age. RESEARCHDESIGNANDMETHODS--In 1998, 1,143 primary care patients with type 2 diabetes participated in the ZODIAC study. Because blood was drawn for 867 patients (76%) and confounders were missing for 19 patients, the final study sample comprised 848 patients. After a follow-up time of 10 years, we used Cox proportional hazard models to evaluate the relationship between MR-proANP and (cardiovascular) mortality. Harrell C statistic was used to compare models with and without MR-proANP. The regression analyses were repeated without MR-proANP for patients aged older than 75 years. RESULTS--Median MR-proANP in the total study sample was 75 pmol/L (interquartile range, 48-124 pmol/L). During follow-up, 354 (42%) out of 848 patients had died, of whom152 (43%) deaths were attributable to cardiovascular factors. MR-proANP was independently associated with all-cause and cardiovascular mortality, irrespective of age. During old age, there was a significant inverse relationship between blood pressure and mortality. This relationship did not change after adjustment for MR-proANP. CONCLUSIONS--MR-proANP is independently associated with mortality in patients with type 2 diabetes. MR-proANP did not influence the inverse relationship between blood pressure and mortality in elderly patients. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
10. Practice Nurses as Main Care-Providers for Patients with Type 2 Diabetes in a Primary Care Setting: A Randomized Controlled Trial.
- Author
-
Houweling, Sebastiaan T., Kleefstra, Nanne, Groenier, Klaas H., Meyboom-De Jong, Betty, and Bilo, Henk J.
- Subjects
- *
NURSES , *PEOPLE with diabetes , *TYPE 2 diabetes , *GENERAL practitioners , *HYPOGLYCEMIC agents , *PRIMARY care , *MEDICAL care - Abstract
The Netherlands will face a shortage of general practitioners (GPs) in the near future. In order to maintain quality of care for the increasing number of patients with type 2 diabetes (DM2), treatment of DM2 in the primary care setting is increasingly taken over by practice nurses (PNs). In a randomized controlled study, we investigated whether medical treatment (including prescriptions according to protocol), quality of life (SF-36), diabetes related complaints (DSC-R), and patient satisfaction (PEQD) were at least equal to care provided by GPs; 206 patients from five general practices participated. The intervention group was treated by PNs and the control group received "standard" care from their own GPs. After fourteen months, the care in the two groups was comparable according to the clinical parameters (HbA1c, blood pressure (BP) and lipid profile). In the group which was treated by the PNs, significantly more patients were referred to specialists including the ophthalmologist according to protocol (71% vs. 37% (p<0.01)). Furthermore, more action was undertaken when the patient had critical foot problems (57% vs. 27% (p<0.01)), and medication dosages were raised more often when considered necessary, except for lipid lowering drugs (hypoglycaemic agents: 83% vs. 50% (p<0.01); antihypertensive agents: 50% vs. 29% (p<0.01)). The overall quality of life and the number of complications related to diabetes were equal in the two groups. Patients were more satisfied with the care they received from the PNs than with the care provided by the GP (PEQD score: 66 vs. 52 (p<0.01)). This study allows the conclusion that PNs who work with strict protocols are capable to offer effective cam to patients with DM2 in a primary care setting. PNs follow the quality guidelines, as formulated by the Dutch General Practitioners' College, more consistently than GPs, saving GPs time, whilst providing care of good quality. [ABSTRACT FROM AUTHOR]
- Published
- 2007
11. Health-Related Quality of Life and Mortality in a General and Elderly Population of Patients With Type 2 Diabetes (ZODIAC-18).
- Author
-
Landman, Gijs W. D., Van Hateren, Kornelis J. J., Kleefstra, Nanne, Groenier, Klaas H., Gans, Rijk O. B., and Bilo, Henk J. G.
- Subjects
- *
QUALITY of life , *OLDER people , *TYPE 2 diabetes , *DIABETES , *MORTALITY , *PEOPLE with diabetes - Abstract
OBJECTIVE-- Diabetes negatively impacts the health-related quality of life (HRQOL) of patients with type 2 diabetes. An earlier analysis showed HRQOL to be associated with mortality, which suggests that measuring HRQOL could have clinical implications. We studied the association between HRQOL and total and cardiovascular mortality in patients with type 2 diabetes during long-term follow-up and specifically focused on old age and sex differences. RESEARCH DESIGN AND METHODS-- HRQOL was measured in a prospectively followed cohort of 1,353 patients with type 2 diabetes using the RAND-36. Cox proportional hazard models were used to measure the independent effect of baseline HRQOL on mortality. RESULTS-- During a mean follow-up of 9.6 years, 570 (42%) patients died, 280 of whom died of cardiovascular disease (49%). The Physical Component Score (PCS) and the Mental Component Score (MCS) were inversely associated with total mortality, with hazard ratios of 0.988 (95% CI 0.983-0.993) and 0.990 (95% CI 0.985-0.995), respectively. A 10-point-higher score on the PCS and MCS decreased the risk for total mortality by 11 and 10%, respectively. An inverse relationship with mortality was also seen for men, women, and for patients aged >75 years. Mental health was significantly related to mortality in men but not in women. CONCLUSIONS-- Lower physical and mental HRQOL was associated with a higher total mortality and cardiovascular mortality in patients with type 2 diabetes; this is also the case when studying men and women and the elderly separately. The dimension mental health, related to depression and anxiety, was only associated with mortality in men, not in women. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
12. The Lipid Profile and Mortality Risk in Elderly Type 2 Diabetic Patients: A Ten-Year Follow-Up Study (ZODIAC-13).
- Author
-
van Hateren, Kornelis J. J., Landman, Gijs W. D., Kleefstra, Nanne, Logtenberg, Susan J. J., Groenier, Klaas H., Kamper, Adriaan M., Houweling, Sebastiaan T., and Bilo, Henk J. G.
- Subjects
- *
HIGH density lipoproteins , *BLOOD lipids , *LIPID synthesis , *DIABETES , *MORTALITY , *TYPE 2 diabetes , *PEOPLE with diabetes , *OLDER patients , *MEDICAL care for older people , *THERAPEUTICS , *MEDICAL care - Abstract
Background: The precise relationship between the lipid profile and mortality in elderly patients with type 2 diabetes mellitus (T2DM) remains unclear. The aim of this study was to investigate the relationship between the lipid profile over time, and mortality in elderly patients with T2DM. Methods and Findings: In 1998, 881 primary care patients with T2DM aged 60 years and older participated in the ZODIAC study, a prospective observational study. The cohort was divided into two age categories: 60-75 years and older than 75 years. Updated means of all lipid profile indices were calculated after a median follow-up time of 9.8 years. These values were used as time dependent covariates in a Cox proportional hazard model. The cholesterol-HDL ratio and LDL-cholesterol were positively related to both all-cause and cardiovascular mortality in the low age group. In contrast, except for the triglyceride level, none of the other lipid profile indices were related to all-cause mortality in patients aged over 75 years. The mortality risk decreased by 17% (95%CI: 5% to 27%) for each 1 mmol/L higher serum level of triglycerides. The relationships between the various lipid profile indices and cardiovascular mortality were not significant. However, the results were different after stratification for diabetes duration. In the subgroup of elderly patients with a diabetes duration of 8 years and longer, higher lipids were predictive of increased cardiovascular mortality. The main limitation of this study is its observational design, which prevents us drawing conclusions about causality. Conclusion: Although the lipid profile was not predictive in the overall group of elderly patients, higher lipids were related to increased cardiovascular mortality in patients with diabetes of long duration. In order to make valid recommendations concerning lipid-lowering treatment, a randomized controlled trial or a meta-analysis concerning this specific population is mandatory. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.